Quality Medical and Laboratory Practice in Cellular Therapy
|
|
- Crystal Spencer
- 5 years ago
- Views:
Transcription
1 Quality Plans: Development and Implementation ISCT Annual Meeting May 24, 2010 Lizette Caballero, B.S., M.T.(ASCP) Laboratory Manager Florida Hospital Cellular Therapy Laboratory
2 Quality Plan: Development and Implementation Show hands How many attendees work for: Clinical Program Collection Facility Processing Facility
3 OBJECTIVES Discussion of quality management goals and structure. Share my experience on how we developed a quality plan. Describe deficiencies related to the quality management section and provide tools/ideas to avoid them.
4 Goals of Quality Management Ensure credibility of outcomes Improve patient safety and quality of processes Significantly reduce errors Quality Medical and Laboratory Practice in Cellular Therapy Emphasize measures to investigate, detect, assess, correct, and prevent errors Catherine Bollard, MD, FACT Quality Management Webinar
5 Quality Management Program The Quality Management Program can be related to the institutional program in several ways, including: Institutional Program Institutional SOPs Applicant QM Plan Institutional QM Program Program QM Program Applicant- Specific SOPs Nested within the Institutional QM Program Program Shared components QM with Program the Institutional QM Program Institutional QM Program Program QM Program Completely separate from the QM Program Catherine Bollard, MD, FACT Quality Management Webinar
6 QM Plan vs Policies vs Procedures Quality Management Plan Example: There is a system for detecting, evaluating, documenting, and reporting errors, accidents, suspected adverse events, biological product deviations and complaints. Policies All incidents, deviations, errors, and unusual occurrences in the transplant program that affect the quality of patient care should be reported, analyzed and corrected. Procedures 1. Document complaints or deviations from errors. 2. Investigate, track and analyze. 3. Determine corrective action and follow up.
7 Elements of a Quality Management Plan 1. Structural Requirements Responsibility for QM program, organizational chart, personnel requirements, process for development and implementation of processes, policies, and procedures. 2. Assessment and Reporting Outcome analysis, audits, validations, and qualifications, evaluation of competency and proficiency, management of cellular products with positive microbial results, system for detection, evaluation, and reporting of accidents, errors, and adverse events. 3. Information and Document Control Mechanism for document control, process for product tracking, mechanisms to ensure continuous operations when information technology fails. Catherine Bollard, MD, FACT Quality Management Webinar
8 Location Overview of Our Program Clinic and Cellular Therapy Lab CTL BMT Unit (3rd Floor)
9 Transplant Program Structure Out Patient Clinic (FCCT) Staffed by FPMG (Florida Physician Management Group) In Patient Unit (BMTU)- 16 Beds Staffed by Florida Hospital Cellular Therapy Laboratory (CTL) Staffed by Florida Hospital Collection Facility Outsourced to Florida s Blood Centers (FBC)
10 HOW WE DID IT!!
11 Quality Program Development: How we did it Team Quality Manager Processing Laboratory Manager Program Director Office Manager (Clinic) BMT Unit Nurse Manager Quality Plan developed following FACT standards D4. Quality Plan shared by Out Patient, In Patient Clinic and Processing Laboratory- 28 pages.
12 Hematopoietic Progenitor Cell Transplant Program 0816.v4 Orlando, Florida Title: Transplant Program Quality Management Plan 1. PRINCIPLE: 1.1. Quality improvement is driven by the requirements of regulatory and accrediting agencies. This quality system conforms to the requirements of the FDA, FACT, NMDP, CIBMTR, JCAHO, CAP, CLIA, ASHI, and other accrediting organizations. The policies of the quality system are described in greater detail within this document and within the departments comprising the Transplant Program. Departments of the Transplant Program include: Florida Center for Cellular Therapy (FCCT), Florida Hospital Cancer Institute Cellular Therapy Lab (CTL), and Florida Hospital BMT Unit. 2. PURPOSE: 2.1. The purpose of the Quality Management Program is to constantly verify and improve the quality of services. We promote effective and efficient utilization by focusing on the analysis of patterns and trends in performances as they relate to clinicians needs and patient outcomes. 3. SCOPE: 3.1. This Quality Management Program incorporates information from clinical and processing areas. The contracted apheresis collection facility s quality activities are reflected in their Quality Management Plan.
13 Quality Program Development: How we did it What to do when writing a Quality Plan: Summarize and reference policies and procedures. Example: D4.5.1 The Quality Management Plan shall include or summarize and reference, a system for document control.
14 Hematopoietic Progenitor Cell Transplant Program 0816.v4 Orlando, Florida Title: Transplant Program Quality Management Plan 1. RECORD REVIEW AND DOCUMENT CONTROL: There is a mechanism in place for document control and for regular review of records relating to cellular therapy product processing, storage, release, transportation, transplantation, and product infusion The following is the current list of all critical documents that adhere to document control system requirements: SOPs Forms Worksheets Validation Plans Consent Forms Standing Orders 1.2. Refer to FH/FCCT SOP #0800 Instructions for Preparing, Implementing, and Reviewing Standard Operating Policies and/or Procedures and Associated Forms for the Clinical Program and CTL SOP # Policy for Preparing, Implementing and Reviewing SOPs and Associated Forms require the following elements: A numeric or alphanumeric identifier is assigned to each documented within the system Signature of the Approving Individual, the Approval Date, and the Effective Date Protection to prevent documents undergoing accidental or unauthorized modification Documentation of training associated with each SOP release and revision.
15 Quality Program Development: How we do it Working with an outsource service (Collection Facility). How do we maintain communication and follow standards? Written agreement including role and responsibilities. Communication between Collection/Clinic/CTL. Packet with donor eligibility, current H&P, signed consents, verification of line placement, vein assessment, lab work and apheresis order is given to collection staff on the first day of collection.
16 Quality Program Development: How we do it Communication (Cont d) A report is generated and sent to FBC with data from each collection. The report is reviewed and signed by the FBC medical director and a copy is faxed back to CTL.
17 Donor Name: MRI# Recipient Weight (Kg): CD 34 Cell Dose (Total) Requested (X10 6 /kg): Machine Serial Number: Peripheral Blood WBC (X10 6 /ml) Hgb% Platelet (X10 6 /ml) CD34% CD34/uL Date: Date: Date: Date: Date: Day Number Day Number Day Number Day Number Day Number Pre Post Pre Post Pre Post Pre Post Pre Post Product Information Unique Identifier Product Volume (mls) WBC (X10 6 /ml) HCT% Gran% MNC% CD34% CD34 Dose(X10 6 /kg) CD34 Collection Efficiency (%) QC Information Day Number Was Efficiency Yield greater than 20% each day? Was total CD34 dose obtained? Product(s) Satisfactory for infusion (pending microbiology results) Day Number Day Number Day Number YES YES NO NO Day Number YES NO If NO Identify Product and give reason: Review Information: Processing Facility Collection Facility Lab Director/Designee Signature Date Medical Director/Designee Signature Date Print Name Please Fax back to the CTL after review Print Name Form Av.1(10/24/2008) FBC Colelction Data Sheet Page 1 of 1
18 Quality Program Development: How we do it Communication (Cont d) Collection Facility staff attend weekly meetings where upcoming collections are discussed. Collection Facility Medical Director attends monthly QA meetings. Positive Culture report is sent to collection facility medical director for review and signature.
19 Quality Program Function Outline Process improvement team: Monthly QA/QI Meetings (Collection and Lab representative present) Policy review committees Daily Inpatient Unit rounds. Weekly Patient Management Meeting (upcoming transplants). Weekly outpatient clinic patient review. Weekly Cellular Therapy Lab meeting with Medical Director. Bi-weekly Multi-disciplinary Tumor board meeting. Monthly FBC/FCCT Directors Meeting.
20 Processing Citations D10 7% D6 10% Other D8 4% 5% D4 28% Quality Management Section D5 10% D9 10% D7 12% D2 14% FACT Quality Management Webinar
21 Quality Management Citations in Processing Inspections Positive microbial culture results (D4.9) Include, or summarize and reference, such results in the QM Plan Be sure all required elements are addressed Be specific If treated as a variance: The procedures must specify this All required elements in D4.9 must be included Perform procedure adequately Superficial investigation, documentation, and reporting does not address the problem
22 Hematopoietic Progenitor Cell Transplant Program 0816.v4 Orlando, Florida Title: Transplant Program Quality Management Plan leadership to be monitored, such as blood transfusions, falls, patient satisfaction, chemotherapy administration, and pain management. 2. MANAGEMENT OF CELLULAR THERAPY PRODUCTS WITH POSITIVE MICROBIAL CULTURE RESULTS: 2.1. All bacterial and fungal contamination of HPC-A, HPC-M, and TC-T products is monitored and documented. Microbiology reports and contamination documentation is kept in the CTL patients file. Contaminated products are reviewed quarterly by the QA/QI Committee. Trends are identified and an action plan formulated. The Manager of the Cellular Therapy Laboratory presents a report for review and discussion quarterly, or sooner, as applicable. Refer to CTL SOP # Guidelines for the Management of Culture Positive Component 2.2. Documentation and product labeling Refer to CTL SOP # Labeling of HPC 2.3. Release of the product from the distribution facility, including identification of authorized individuals and criteria for produce release. Refer to CTL SOP # Product Release Criteria 2.4. Investigation of cause- Refer to CTL SOP # Errors/Unusual Occurrence Reporting and Management 2.5. Notification of transplant physician, collection facility and/or Cell Process Facility as applicable- Refer to CTL SOP # Guidelines for the Management of Culture Positive Component 2.6. Notification of the recipient prior to infusion Refer to FH/FCCT SOP #0810 Allogeneic Hematopoietic Progenitor Cell (HPC) Recipient Evaluation and SOP #0813 Autologous Hematopoietic Progenitor Cell (HPC) Recipient Evaluation and Selection Recipient follow-up and outcome analysis Refer to FH/FCCT SOP #0810 Allogeneic Hematopoietic Progenitor Cell (HPC) Recipient Evaluation and Selection and SOP #0813 Autologous Hematopoietic Progenitor Cell (HPC) Recipient Evaluation and Selection.
23 Quality Management Citations in Processing Inspections Validation Must be included, or summarized or referenced, in the QM Plan. Even if a procedure has been in use for years, it still needs to be validated and/or verified. Documentation must be available to the inspector. Review and acceptance of validation studies must be documented by appropriate individual from Quality Management.
24 Hematopoietic Progenitor Cell Transplant Program 0816.v4 Orlando, Florida Title: Transplant Program Quality Management Plan specifications. Results of all such test and procedures become part of the permanent records of the product processed Communicable disease testing is performed using FDA approved tests in an FDA registered laboratory that is accredited and licensed in accordance with applicable governmental regulations All other tests, not performed by the Processing Facility, are performed by a laboratory certified by CLIA For tests performed within the Processing Facility, there is documentation of ongoing proficiency testing as designated by the Processing Facility Director. The results are reviewed by the Processing Facility Director or designee and outcomes reviewed with the staff Cellular therapy products that do not meet release or donor-eligibility requirements are distributed only if there is documented urgent medical need for the product. Documentation includes, at a minimum, the approval of the recipient s physician and the Processing Facility Medical Director or other designated physician Notification of the recipient s physician of testing and screening results for ineligible donors is documented. 2. VALIDATION AND QUALIFICATION OF CRITICAL REAGENTS, EQUIPMENT, AND PROCEDURES: 2.1. There is a process in use for validating and verifying all reagents, equipment, and procedures refer to CTL SOP# Validation Equipment, Process or Procedure The Program Director and the Quality Assurance Manager review and approve all validation studies Changes to a process are verified or validated to ensure that they do not create an adverse impact anywhere in the operation.
25 FHCI Cellular Therapy Laboratory 2501 North Orange Ave. Suite 786 Orlando, FL Validation Plan VALIDATION TITLE: Retrospective Analysis of Allogeneic Bone Marrow Collections Validation of: Equipment Process Product (Check all that apply) Type: (IQ) Installation Qualification (OQ) Operation Qualification (PQ) Performance Qualification I. PURPOSE OF VALIDATION This validation will provide a retrospective review of the allogeneic bone marrow collections performed by the bone marrow collection facility at Florida Hospital to establish acceptable ranges for MNC, TNC, sterility, and viability based on the data collected. II. SYSTEM DESCRIPTION Allogeneic bone marrow harvests performed by the physicians and physician s assistants (P.A.) of the bone marrow collection facility at Florida Hospital will be evaluated for total MNC, total TNC, MNC/kg (recipient), TNC/kg (recipient), sterility, volume (ml/kg recipient) and viability of the product collected. Engraftment data will be analyzed to determine successful outcome. This retrospective analysis will be used to establish acceptable ranges for future allogeneic bone marrow harvests. III. RESPONSIBILITY ASSIGNMENT- Document name in table (Signatures follow plan and results). Validation Plan written by (manager): Validation Plan reviewed by (facility director): Validation Plan approved by (medical director): Susan Ingersoll, Ph.D./Lizette Caballero, MT (ASCP) John R. Edwards, M.D. Vijay Reddy, M.D., Ph.D. Validation performed by (staff): Validation Results evaluated by (manager): Validation Results reviewed by (facility director): Validation Results approved by (medical director): Susan Ingersoll, Anginett Batista, Lizette Caballero Susan Ingersoll, Ph.D./Lizette Caballero, MT (ASCP) John R. Edwards, M.D. Vijay Reddy, M.D., Ph.D. IV. VALIDATION PLAN A. List SOPs, personnel, equipment, and supplies required.
26 Quality Management Citations in Processing Inspections The Quality management Plan shall include, or summarize and reference, policies and procedures and a timetable for conducting and reviewing audits of the processing Facility s activities Results of the audits shall be used to recognize problems, detect trends and identify improvement opportunities.
27 Audit of Product Processing, Distribution & Infusion Records FHCI Cellular Therapy Lab, 2501 North Orange Ave. Ste. 786 Orlando, FL Recipient Name Donor Name Product Name Recipient ID Donor Patient ID Collection Date Instructions: Review the forms listed below that may be completed in association with product processing or infusion for accuracy and/or completeness, then mark as Acceptable or Unacceptable. If Unacceptable, please list comment # and comment. Write N/A if not applicable. PROCESSING DOCUMENTATION Donor Infec Dx Mark testing 30 days of HPC or 7days of TC-T collect or labeled w/ Warning labels Donor History Questionnaire completed and signed by donor and person obtaining consent Consent for Mobilization and Collection & Storage and Discard of HPC signed Consent for Treatment signed Donor Eligibility Form completed with test results and signed by Medical Director and Transplant physician Final Declaration of Donor Eligibility completed and signed by Medical Director and Transplant Physician HPC Processing Order Form signed by the requesting MD Collection Data Sheet from day of collection (from FBC) in the chart Daily QC performed on each day of processing Do the product modifications ordered on the HPC Processing Order form was performed? Component Control Record completed for each product Daily Cell counts Printouts Donor/recipient collection date ABO/Rh compared to previous typing for consistency (daily) Audit Tool Accurate Y or N Complete Y or N Acceptable Check Unacceptable Check Comment Number
28 FHCI Cellular Therapy Laboratory 2501 North Orange Ave. Suite 786 Orlando, FL Audit Results Audit TITLE: Audit of Product Processing, Distribution and Infusion Records Audit NUMBER:A010 Audit of: Equipment X Process Product Label Form I. PURPOSE OF AUDIT Forms and records associated with product processing or infusion will be checked for accuracy and/or completeness. II. SYSTEM DESCRIPTION Patient s chart will be reviewed following checklist form B. Unacceptable finding will be described in the comments section. Ach audit will be reviewed by the Quality Assurance Representative and Medical Director. III. RESPONSIBILITY ASSIGNMENT- Document name in table (Signatures follow plan and results). Audited by: Audit Results evaluated by: Audit Results reviewed by: Quality Management review by: A. Establish the number of test samples required. 3 patient s charts Audit Report B. Describe Audit Results (if no corrective action/process improvement is required proceed to step VI). 3 out of 3 records were completed and accurate. C. Determine data/records to be collected to fix findings (if applicable). D. Establish corrective actions or process improvement to be made as a result of this audit. IV. Establish expected date of completion of the corrective action V. Establish expected date to re-audit to verify that the corrective actions were effective. VI. CONCLUSION A. Determination of acceptance for audit/corrective action findings: B. The following department(s) and personnel were informed of findings: VIII. AUDIT RESULTS AND FOLLOW UP (IF APPLICABLE) SIGNATURES Laboratory Supervisor: Medical Director: Quality Assurance: Date: Date: Date: Corrective Action Results approved: N/A YES NO (if not approved, attach revised plan.)
29 HOW THE TEAM FELT!
30 Roadblocks to Success Poor Communication Difficulties trying to get the team together. Too many meetings. Lack of Understanding What is a Quality Plan? Why we need one? Why we need SOPs? I know we do it; why do I need to document? Minimal or Non Staff Engagement Think, talk, look for quality in everything you do. Non-clinical personnel. Resistance to Change in Culture Non punitive to process improvement mentality. Encouragement to report mistakes and close calls.
31 Acknowledgement Cellular Therapy Laboratory Anginett Batista Joanne Sullivan Teshia Wright FACT
32 Q & A Session Collection How do centers avoid ineligible donors due to pending testing? How do centers come up with release criteria for their products? Collection Facility Processing Facility What is required to be qualified as a trainer at your institution? Give examples of audits at your institution? How often? What is the process for analysis of audits and identification of areas for improvement? Processing Who was part of the team during the development of your QMP? How do you communicate with other departments when something fails? Release criteria not achieved, adverse reaction, etc. How do you document this communication?
33
CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION DOCUMENT SUBMISSION REQUIREMENTS
CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION DOCUMENT SUBMISSION REQUIREMENTS FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing and Administration,
More information7 th Edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration
7 th Edition FACT-JACIE International Standards for Hematopoietic Cellular Therapy Product Collection, Processing, and Administration Summary of Changes This document summarizes the major changes made
More informationFACT (Foundation for the Accreditation of Cellular Therapy): Elizabeth Perry, MD
FACT (Foundation for the Accreditation of Cellular Therapy): An Inspector s View Elizabeth Perry, MD 11/7/08 Standards FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing,
More informationList of Policies and Standard Operational Procedures (SOPs) for cell collection, processing and transplantation programmes
Format of SOPs (SOPs) for cell collection, processing and transplantation programmes There must be an SOP covering the procedure of preparing, implementing and revising all procedures and an SOP for document
More informationProgram: Billings Clinic
Program: Billings Clinic FACT ID: 175 Type: Adult autologous CCN: 11013 Status: Annual report, under review FACT Inspection: NA Accreditation Exp. Date: 02/07/2020 Next CIBMTR Audit: TBD (low numbers)
More informationNational Marrow Donor Program /Be the Match 23rd Edition Standards And Glossary January 1, 2016 Notice and Disclaimer NMDP/Be the Match Standards
National Marrow Donor Program /Be the Match 23rd Edition Standards And Glossary January 1, 2016 Notice and Disclaimer NMDP/Be the Match Standards These standards apply to activities performed by National
More informationPre-inspection documentation
Pre-inspection documentation Introduction... 1 Language... 1 Pre-formatted folder structure... 2 When do I have to send these document?... 2 What does JACIE do with these documents?... 2 How does JACIE
More information5 th Edition FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration Summary of Changes
5 th Edition FACT-JACIE International Standards for Cellular Therapy Product Collection, Processing, and Administration Summary of Changes This document summarizes the changes made to the 5 th edition
More informationPolicy Subject Index Number Section Subsection Category Contact Last Revised References Applicable To Detail MISSION STATEMENT: OVERVIEW:
Subject Objectives and Organization Pathology and Laboratory Medicine Index Number Lab-0175 Section Laboratory Subsection General Category Departmental Contact Ekern, Nancy L Last Revised 10/25/2016 References
More informationINTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION
INTERNATIONAL STANDARDS FOR CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION Third Edition NOTICE These Standards are designed to provide minimum guidelines for facilities and individuals
More informationAbout PACT. PACT Members. Production Assistance for Cellular Therapies. October 11, :00 Noon - 1:00 PM ET
Production Assistance for Cellular Therapies Welcome to the PACT Educational Web Seminar October 11, 2007 12:00 Noon - 1:00 PM ET About PACT An NHLBI-funded initiative committed to the advancement of effective
More informationQuality Management of Apheresis Personnel
In: McLeod BC, Price TH, Weinstein R, eds. Apheresis: Principles and Practice, 2nd Edition Bethesda, MD: AABB Press, 2003 Quality Management of Apheresis Personnel 32 Quality Management of Apheresis Personnel
More informationHematopoietic Cellular Therapy. Accreditation Manual
Hematopoietic Cellular Therapy Accreditation Manual sixth EDITION INTERNATIONAL STANDARDS FOR HEMATOPOIETIC CELLULAR THERAPY PRODUCT COLLECTION, PROCESSING, AND ADMINISTRATION ACCREDITATION MANUAL Guidance
More informationBlood Bank Rotations Goals and Objectives. Rotation Director: Robertson Davenport, M.D.
Blood Bank Rotations Goals and Objectives Rotation Director: Robertson Davenport, M.D. The goal of the First Blood Bank Rotation is for the resident to move from being a Novice (A novice knows little about
More informationAccreditation of Transplantation Centres in South Africa. Preamble
Accreditation of Transplantation Centres in South Africa. Preamble Accreditation is the means by which a centre can demonstrate that it is performing to a required level of practice in accordance with
More informationSTANDARDIZED PROCEDURE ALLOGENEIC /AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION (Adult, Peds)
STANDARDIZED PROCEDURE I. Definition: The infusion of allogeneic /autologous hematopoietic progenitor cells as a part of hematopoetic stem cell transplant or donor lymphocyte infusion. II. Background Information
More informationCAP Most Frequent Deficiencies and How to Avoid Them. March 11, 2015
CAP 2015 Most Frequent Deficiencies and How to Avoid Them Jean Ball MBA,MT(HHS),MLT(ASCP) Inspection Services Team Lead Laboratory Accreditation Program March 11, 2015 Objectives: Participants will be
More informationStandards, Guidelines, and Regulations
Standards, Guidelines, and Regulations Theresa C. Stec BA, MT(ASCP) Biovigilance Program Manager Surgical System Administrator Perioperative Services Baystate Medical Center Springfield, MA Standards,
More informationWORLD MARROW DONOR ASSOCIATION WMDA INTERNATIONAL STANDARDS FOR UNRELATED HAEMATOPOIETIC STEM CELL DONOR REGISTRIES
1 of 23 pages World Marrow Donor Association International Standards for Unrelated Haematopoietic Stem Cell Donor Registries Document type WMDA Standards 2017 WG/Committee BCST Document reference Approved
More informationPRE-INSPECTION QUESTIONNAIRE INSTRUCTIONS
PRE-INSPECTION QUESTIONNAIRE INSTRUCTIONS! Submit copies of all documents or records outlined below. If you do not have the required information, indicate whether or not you expect to have it at the time
More informationPURPOSE: This policy provides an overview of SHANDS Jacksonville Laboratory s commitment to the care and safety of the patients we serve.
PAGE 1 of 5 TITLE: Provision of Care Regarding Laboratory Services PURPOSE: This policy provides an overview of SHANDS Jacksonville Laboratory s commitment to the care and safety of the patients we serve.
More informationRegulatory,Quality & Emergency Preparedness. MaryBeth Parache Director, Quality Affairs New York Blood Center
Regulatory,Quality & Emergency Preparedness MaryBeth Parache Director, Quality Affairs New York Blood Center 1 Regulatory 2 Who regulates us? Food and Drug Administration (FDA) Blood, tissue, HCT/P, medical
More informationPatient Blood Management Certification Revisions
Issued October 3, 07 Patient Blood Management Certification Revisions Patient Blood Management (PBM) Certification Program Assessments: Internal and External (PBMAM) Chapter Standard PBMAM. The program
More informationHeart of America POC Group Quality Management Making it Meaningful
Heart of America POC Group Quality Management Making it Meaningful Maximize Your Existing Quality Management System to Deliver Greater Value Georgine Paulus, BSMT(ASCP) Senior Staff Inspector College of
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationAMERICAN BOARD OF HISTOCOMPATIBILITY AND IMMUNOGENETICS Laboratory Director. Content Outline
1. Administration and Management (40 Items) A. Quality Assurance (16 items) 1. Determine if technical staff has received training and continuing education 2. Select external laboratory proficiency testing
More informationThe Transfusion Medicine diplomate will respect the rights of the individual and family and must
Competency Portfolio for the Diploma in Transfusion Medicine Guide for AFC-Diploma Committees/Working Groups, Educators 2012 VERSION 1.0 This portfolio applies to those who begin training on or after July
More informationEDUCATIONAL COMMENTARY KEY COMPONENTS OF AN INDIVIDUALIZED QUALITY CONTROL PLAN
Commentary provided by: E Susan Cease MT(ASCP) Laboratory Manager Three Rivers Medical Center Grants Pass, OR EDUCATIONAL COMMENTARY KEY COMPONENTS OF AN INDIVIDUALIZED QUALITY CONTROL PLAN Educational
More informationThis policy shall apply to all directly-operated and contract network providers of the MCCMH Board.
Chapter: Title: PROVIDER NETWORK MANAGEMENT Approved by: Executive Director Prior Approval Date: 7/30/02 Current Approval Date I. Abstract This policy establishes the standards and procedures of the Macomb
More informationStandards for Laboratory Accreditation
Standards for Laboratory Accreditation 2017 Edition cap.org 2017 College of American Pathologists. All rights reserved. [ T y p e t h e c o m p a n y a d d r e s s ] CAP Laboratory Accreditation Program
More informationJACIE Accreditation 2010 and Beyond
Aims of this presentation JACIE Accreditation 2010 and Beyond Derwood Pamphilon Medical Director, JACIE Explain the current regulatory environment for stem cell transplantation in Europe Discuss stem cell
More informationCAH PREPARATION ON-SITE VISIT
CAH PREPARATION ON-SITE VISIT Illinois Department of Public Health, Center for Rural Health This day is yours and can be flexible to the timetable of hospital staff. An additional visit can also be arranged
More informationPoint of Care Quality Management. Procedure. Approving Authority: President and CEO, Keith Dewar
Subject/Title Point of Care Quality Management Procedure Approving Authority: President and CEO, Keith Dewar Manual: Reference Number: 812-1 Effective Date: Dec 6 th, 2016 Revision Dates: Classification:
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationPOL:02:UP:001:07:NIBT PAGE 1 of 6 ISSUE DATE: 12 DECEMBER 2014 EFFECTIVE DATE: 9 JANUARY 2015
POL:02:UP:001:07:NIBT PAGE 1 of 6 Northern Ireland Blood Transfusion Service POLICY DOCUMENT Document Details Document Number: POL:02:UP:001:07:NIBT Supersedes Number: POL:02:UP:001:06:NIBT Document Title:
More informationIndividualized Quality Control Plan (IQCP) Frequently Asked Questions Date: May 5, 2015 (last updated 08/21/2017)
Topic: Individualized Quality Control Plan (IQCP) Frequently Asked Questions Date: May 5, 2015 (last updated 08/21/2017) Click on the links below to be taken to a specific section of the FAQs. General
More informationPersonnel. From RLM, COM, GEN and TLC Checklists
Personnel From RLM, COM, GEN and TLC Checklists The laboratory should have an organizational plan, personnel policies, and job descriptions that define qualifications and duties for all positions. Personnel
More informationRe: Proposed Rule; Medicare Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System FY 2018 (CMS 1677 P)
June 9, 2017 Seema Verma Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS 1677 P Mail Stop C4 26 05 7500 Security Boulevard Baltimore, MD 21244
More informationSample. A guide to development of a hospital blood transfusion Policy at the hospital level. Effective from April Hospital Transfusion Committee
Sample A guide to development of a hospital blood transfusion Policy at the hospital level Name of Policy Blood Transfusion Policy Effective from April 2009 Approved by Hospital Transfusion Committee A
More information20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice
20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice Nursing Research/ Evidence-Based Practice Checklist (Version 31 January 2012) Specify the date in the left column when
More informationHAEMOVIGILANCE POLICY
REASON FOR ISSUE: New document describing Haemovigilance System 1. INTRODUCTION NZBS has adopted the Council of Europe definition that states that haemovigilance is: The organised surveillance procedures
More informationPRE-INSPECTION QUESTIONNAIRE INSTRUCTIONS
PRE-INSPECTION QUESTIONNAIRE INSTRUCTIONS Submit copies of all documents or records outlined below. If you do not have the required information, indicate whether or not you expect to have it at the time
More informationIQCP. Ensuring Your Laboratory s Compliance With Individualized Quality Control Plans. November/December 2016
IQCP Ensuring Your Laboratory s Compliance With Individualized Quality Control Plans November/December 2016 Objectives Describe the different components of an IQCP Review new CAP checklist requirements
More informationStandards for Biorepository Accreditation
Standards for Biorepository Accreditation 2013 Edition cap.org Biorepository Accreditation Program Standards for Accreditation 2013 Edition Preamble A biorepository is an entity that receives, stores,
More informationSARASOTA MEMORIAL HEALTH CARE SYSTEM CORPORATE POLICY
SARASOTA MEMORIAL HEALTH CARE SYSTEM CORPORATE POLICY TITLE: ADMINISTRATION OF BLOOD AND EFFECTIVE DATE: REVIEWED/REVISED DATE: POLICY TYPE: 10/15/79 08/31/17 Clinical 1 of 7 Non-Clinical Job Title of
More informationScope of Service. Department Mission
Scope of Service Department Mission Scope of Services Provided The Department of Laboratory Services provides a wide array of testing and other services to Memorial Health System s patients, and to other
More informationCE Update [generalist compliance/regulation management/administration and training] COLA Accreditation An Educational Experience
your lab focus 284 CE Update [generalist compliance/regulation management/administration and training] COLA Accreditation An Educational Experience Jennifer L. Rivers, Catherine M. Johnson, MT(ASCP) COLA,
More informationBenchmarking and Key Metrics Utilized by HSCT Administrators. Clint Divine, MBA, MSM Administrative Director, BMT
Benchmarking and Key Metrics Utilized by HSCT Administrators Clint Divine, MBA, MSM Administrative Director, BMT 1 When you ve seen one HSCT program, you ve seen one HSCT program Although, there are many
More informationHCT Coding & Documentation
HCT Coding & Documentation HCT REIMBURSEMENT SERIES marrow.org/reimbursement This educational series is designed by the National Marrow Donor Program (NMDP) Payor Policy team, in conjunction with the American
More informationCompounded Sterile Preparations Pharmacy Content Outline May 2018
Compounded Sterile Preparations Pharmacy Content Outline May 2018 The following domains, tasks, and knowledge statements were identified and validated through a role delineation study. The proportion of
More informationRisk Management in the ASC
1 Risk Management in the ASC Sandra Jones CASC, LHRM, CHCQM, FHFMA sjones@aboutascs.com IMPROVING HEALTH CARE QUALITY THROUGH ACCREDITATION 2014 Accreditation Association for Conflict of Interest Disclosure
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationALLIED PHYSICIAN IPA ADVANTAGE HEALTH NETWORK IPA ARROYO VISTA MEDICAL IPA GREATER ORANGE MEDICAL GROUP IPA GREATER SAN GABRIEL VALLEY PHYSICIANS IPA
ALLIED PHYSICIAN IPA ADVANTAGE HEALTH NETWORK IPA ARROYO VISTA MEDICAL IPA GREATER ORANGE MEDICAL GROUP IPA GREATER SAN GABRIEL VALLEY PHYSICIANS IPA QUALITY IMPROVEMENT PROGRAM 2010 Overview The Quality
More informationPediatric Hematology/Oncology/HSCT Clinical Privileges
Name: Effective from / / to / / Initial privileges (initial appointment) Renewal of privileges (reappointment) All new applicants should meet the following requirements as approved by the governing body,
More informationACCOUNT NO. MED. REC. NO. NAME BIRTHDATE. Patient Identification ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK ( ) TO BE ACTIVE.
PO7071 *PO7071* Page 1 of 4 ALL MUST BE MARKED IN INK WITH A CHECKMARK ( ) TO BE ACTIVE. Weight: kg Height: cm Allergies: Treatment Start Date: Date(s) of Transfusion(s): Current Labs: WBC: Hgb/Hct: Platelets:
More informationObjectives Top Ten Cited Deficiencies for Acute Care Facilities April 21, 2015
2014 Top Ten Cited Deficiencies for Acute Care Facilities April 21, 2015 Michele Kala, MS, RN Director of Accreditation and Certification Objectives Understanding of the top scored deficient HFAP standards
More informationCollege of American Pathologists 325 Waukegan Road, Northfield, Illinois Advancing Excellence
Attachment A College of American Pathologists 325 Waukegan Road, Northfield, Illinois 60093-2750 800-323-4040 http://www.cap.org Advancing Excellence August 31, 20XX Reference Number: 2365 CAP Number:
More information1. General description
Oncology Clinic Learning Activities: Preceptor: Jeni Ludescher, PharmD; Tim Samuelson, RPh Work area: Luther Building North, Cancer Center Hours: 8:00-16:30 Phone: (715) 838-5131 Email: ludescher.jeni@mayo.edu;
More informationClinical Interdepartmental Policy and Procedure
Clinical Interdepartmental Policy and Procedure Policy: Staff Response to Medical Errors/Adverse Events Policy Number: MR-006 Joseph S. Gordy, CEO Signature: Flagler Hospital Originator: President Coordinating
More informationArizona Department of Health Services Licensing and CMS Deficient Practices
Arizona Department of Health Services Licensing and CMS Deficient Practices Connie Belden, RN., Bureau of Medical Facility Licensing August 8, 2013 General Comments Deficient Practices per visit Trend
More informationLaboratory Risk Assessment: IQCP and Beyond. Ron S. Quicho, MS Associate Project Director Standards and Survey Methods, Laboratory July 18, 2017
Laboratory Risk Assessment: IQCP and Beyond Ron S. Quicho, MS Associate Project Director Standards and Survey Methods, Laboratory July 18, 2017 Objectives Explain the importance of risk assessment in the
More informationDanette L. Godfrey, MS, MT (ASCP) Senior Product Manager, Accreditation Programs cap.org
CAP Accreditation 2012 and Beyond Danette L. Godfrey, MS, MT (ASCP) Senior Product Manager, Accreditation Programs cap.org AGENDA 50 Years of Accreditation 2011 Checklist Release CAP Accreditation Readiness
More informationSection II: Food Service. MPR 1 Plan Review
Plan Review Michigan Local Public Health Accreditation Program MPR 1 Plan Review Materials necessary for auditing the MPR Plan review log book or tracking system Facility files selected for the review
More informationFulton County Medical Center. Position Description. Pathologist, Laboratory Manager, and Medical Technologist
Fulton County Medical Center Position Description Position Title: Reports To: Medical Laboratory Technician Pathologist, Laboratory Manager, and Medical Technologist Date: September 2004 I Position Summary:
More informationBlood / Blood Products Transfusion A Liquid Transplant
Blood / Blood Products Transfusion A Liquid Transplant Caroline Holt Specialist Practitioner of Transfusion caroline.holt@tgh.nhs.uk Tel : 922 5484 Mob: 07759260044 The Transfusion Team Gillian Lewis Blood
More information3/14/2016. The Joint Commission and IQCP. Objectives. Before Getting Started
The Joint Commission and IQCP Stacy Olea, MBA, MT(ASCP), FACHE Executive Director Laboratory Accreditation The Joint Commission AACC 2015 Objectives Identify the three components of IQCP Determine a starting
More informationOrganization for Economic Co-operation and Development
IGLP document -IRAQ- BAGHDAD English - Or. Arabic Unclassified Organization for Economic Co-operation and Development (2015) 21-Dec-2015 According to criteria of OECD ON TESTING AND CALIBRATION Number
More informationStandards for Forensic Drug Testing Accreditation
Standards for Forensic Drug Testing Accreditation 2013 Edition cap.org Forensic Drug Testing Accreditation Program Standards for Accreditation 2013 Edition Preamble Forensic drug testing is a laboratory
More informationApplicant and Inspector guide to the JACIE inspection process Version 15
Applicant and Inspector guide to the JACIE inspection process Version 15 Issued: 19 July 2017 2/44 Contents INTRODUCTION... 5 SECTION 1 APPLICATION FOR ACCREDITATION... 6 SECTION 3 PRE-INSPECTION DOCUMENT
More informationAuthorized Personnel to Review
October 31, 2017 Page 1 of 7 All documents developed or maintained for the Manufactured Food Regulatory Program Standards ( MFRPS ) are listed below. For each document, the following information is included:
More informationAATB s Report: Adverse Reporting Systems & Requirements
AATB s Report: Adverse Reporting Systems & Requirements TTSN Organ & Tissue Safety Workshop June 5, 2007 Reston, Virginia Scott Brubaker, CTBS Chief Policy Officer American Association of Tissue Banks
More informationUS ): [42CFR ]:
GEN.53400 Section Director (Technical Supervisor) Qualifications/Responsibilities Phase II Section Directors/Technical Supervisors meet defined qualifications and fulfill the expected responsibilities.
More informationSTANDARDS Point-of-Care Testing
STANDARDS Point-of-Care Testing For Surveys Starting After: January 1, 2018 Date Generated: January 12, 2017 Point-of-Care Testing Published by Accreditation Canada. All rights reserved. No part of this
More informationThe CAP Inspection Process
The CAP Inspection Process So you ve accepted an inspection assignment Inspector s Inspection Packet sent from CAP 3 6 months prior to lab s anniversary date Inspection must occur within 3 month window
More information6/28/2016. Questions? Workshop 6 CAP Inspection Preparation Thursday, June 23, 2016
Workshop 6 CAP Inspection Preparation Thursday, June 23, 2016 Allan W. Fraser Jr., CG(ASCP)CM, CCS, CQA(ASQ) Quality Assurance Manager, Quest Diagnostics at Nichols Institute Questions? Have you been inspected
More informationCAP Forensic Drug Testing Accreditation Program Standards for Accreditation
CAP Forensic Drug Testing Accreditation Program Standards for Accreditation Preamble Forensic drug testing is a laboratory specialty concerned with the testing of urine, oral fluid, hair, and other specimens
More informationASCO s Quality Training Program
ASCO s Quality Training Program Project Title: Reduction of Time from Admission to Initiation of Chemotherapy on Inpatient Hematology and Bone Marrow Transplant Services Presenter s Name: Ryan J. Mattison,
More informationBlood and Blood Products Administration
NCAL Patient Care Services 2016 Blood and Blood Products Administration Objectives: On completing this module, you will be able to: Identify blood group systems Describe compatibility requirements List
More informationClinical Molecular Genetics Diagnostic Laboratory
Clinical Molecular Genetics Diagnostic Laboratory University of Miami, Miller School of Medicine BIO-BANKING COMPENDIUM January 2013 Manual of Service 1501 NW 10th Avenue BRB, Room 445 Miami, Florida 33136
More informationTheradex Audit 2013: Findings & Corrective Action
Theradex Audit 2013: Findings & Corrective Action Overview Discuss Findings and CAP for: Informed Consent Content IRB Informed Consent Eligibility Treatment Serious Adverse Events Response General Data
More informationIrradiated blood products - Pathway for requesting To provide healthcare professionals with clear guidance on the use of irradiated blood products.
Document Title: Document Purpose: Document Statement: Document Application: Responsible for Implementation: Irradiated blood products - Pathway for requesting To provide healthcare professionals with clear
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationRichard Haggas Blood Transfusion Quality Manager Leeds Teaching Hospitals NHS Trust
Richard Haggas Blood Transfusion Quality Manager Leeds Teaching Hospitals NHS Trust MHRA Oversees compliance with Blood safety and quality regulations Annual compliance report submitted by each transfusion
More informationJACIE in Europe and Belgium. Ivan Van Riet
JACIE in Europe and Belgium Ivan Van Riet National Jacie representative Ivan.vanriet@uzbrussel.be What is JACIE? Joint Accreditation Committee of the International Society of Cellular Therapy (ISCT) and
More informationInternal Lab Inspections: Are You Inspection Ready? Presented by: Jeanne Mumford, MT(ASCP) Manager, Point of Care Testing, JHM
Internal Lab Inspections: Are You Inspection Ready? Presented by: Jeanne Mumford, MT(ASCP) Manager, Point of Care Testing, JHM Speaker Introductions Jeanne Mumford, MT(ASCP) Manager, Point of Care Testing
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationGCP INSPECTION CHECKLIST
(This list is not all inclusive; item may be added &/or deleted as per the Study/Site/Sponsor/Lab) I. General. Name and address of the clinical trial site Tel. No. & e- mail:. Date of Inspection. Inspection
More information5. returning the medication container to proper secured storage; and
111-8-63-.20 Medications. (1) Self-Administration of Medications. Residents who have the cognitive and functional capacities to engage in the self-administration of medications safely and independently
More informationNURSING CONTINUING EDUCATION 2017 Catalogue
NURSING CONTINUING EDUCATION 2017 Catalogue MISSION VISION VALUES Memorial Sloan Kettering Cancer Center 1275 York Avenue, New York, NY 10065 212-639-6884 nursingceprogram@mskcc.org The Magnet Recognition
More informationCOMPLIANCE PLAN PRACTICE NAME
COMPLIANCE PLAN PRACTICE NAME Table of Contents Article 1: Introduction A. Commitment to Compliance B. Overall Coordination C. Goal and Scope D. Purpose Article 2: Compliance Activities Overall Coordination
More informationClinical Laboratory Standards of Practice
Wadsworth Center Clinical Laboratory Evaluation Program Part 1 General Systems TABLE OF CONTENTS Quality Management System 3 Human Resources 9 Facility Design and Resource Management 23 General Facilities...
More informationSTANDARDIZED PROCEDURE FEMORAL VENOUS BLOOD DRAW (Adult, Peds)
I. Definition The Femoral venous blood draw (FVBD) is the procedure of performing a needle stick into the femoral vein for the purpose of drawing blood work that will assist in lab monitoring. II. Background
More informationCLINICAL CHEMISTRY. Phone: The department is staffed 24 hours a day.
CLINICAL CHEMISTRY Phone: 922-4488 Hours: The department is staffed 24 hours a day. Monday Friday Saturday Sunday Days: 8:00 a.m. - 4:30 p.m. Full Testing Limited Limited Evenings: 4:00 p.m. - 12:30 a.m.
More informationAST Research Network Career Development Grants: 2019 Faculty Development Research Grant
AST Research Network Career Development Grants: 2019 Faculty Development Research Grant The application deadline is 11:59 pm Pacific Standard Time on Wednesday, November 1, 2018. A limited number of grants
More informationJob Description / Performance Evaluation
Job Description / Performance Evaluation Title: Dietary Aide Effective Date: Department: Food and Nutrition Services Job Code: Reports to: Manager of Clinical Nutrition or designee FLSA Status: Signatures
More informationAPEx Program Standards
APEx Program Standards The following standards are the basis of the APEx program. Level 1 standards are indicated in bold. Standard 1: Patient Evaluation, Care Coordination and Follow-up The radiation
More informationIntra-operative Cell Salvage. Competency Assessment Workbook. Trainee: Hospital: Trainer/Supervisor: Date Commenced: Date Completed:
Intra-operative Cell Salvage Competency Assessment Workbook Trainee: Hospital: Trainer/Supervisor: Commenced: Completed: Contents Introduction 1-2 Record of Assessors 4 Confirmation of Required Pre-assessment
More informationComplaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018
Complaints Investigation and Review Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does not represent
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More information